sglt2 inhibitors vs glp-1 and Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Choosing SGLT2 Inhibitors vs GLP-1

Its efficacy in weight loss, blood sugar control, and cardiovascular health make it a valuable tool in improving overall health outcomes

The semaglutide titration continues with 0.5 mg weekly for four weeks, followed by 1.0 mg weekly for four weeks, then 1.7 mg weekly for four weeks, before reaching the target maintenance dose of 2.4 mg weekly

doi: 10.1177/1559827616638018

Endocr Rev

GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca(2+) channels

All Your Options Zepbound Coverage: Other Major Insurers See how other insurers compare on Zepbound coverage: UnitedHealthcare Coverage varies by plan